首页> 外文会议>International Conference on Biosciences and Medical Engineering >The Role of Moringa oliefera-Albumin Combination As A Traditional Medicine to Control The Development of SDF-1 and TER-119~+VLA-4~+ in Diabetes Mice Models
【24h】

The Role of Moringa oliefera-Albumin Combination As A Traditional Medicine to Control The Development of SDF-1 and TER-119~+VLA-4~+ in Diabetes Mice Models

机译:Moringa Oleifera-albumin组合作为一种传统药物,以控制SDF-1和Ter-119〜+ VLA-4〜+在糖尿病小鼠模型中的发育

获取原文

摘要

Diabetes mellitus (DM) is a metabolic disease characterized by hyperglycemia. Hyperglycemia in DM leads to bone marrow dysfunction in the hematopoiesis process of hematopoietic stem cells (HSC). The objective of this research was to analyze the advantage of Moringa oliefera-Albumin (MA) combination to control the development of SDF-1 and TER-119~+VLA-4~+ in bone marrow. Streptozotocin was used to induce diabetes in BALB/c mice. MA was orally administered during 14 days at dose 1 (50% M: 50% A), dose 2 (75% M: 25% A) and dose 3 (25% M: 75% A). Bone marrow cells from mice were isolated on day 15 after treatment, and the profile of SDF-1 and TER-119~+VLA-4~+ cells were analyzed by flow cytometry. The data were statistically analyzed with one way ANOVA (p < 0.05) and Tukey test using SPSS version 16 for Windows. The results showed that all the doses of MA combination could significantly decrease the development of SDF-1 while only dose 2 (75% M: 25% A) effective to increase the development of TER-119~+VLA-4~+. In conclusions, MA combination has a role in controlling the development of SDF-1 and TER-119~+VLA-4~+ at certain dose. Based on the results, we assumed that MA might be one of a good candidate as therapeutic agent for diabetes mellitus.
机译:糖尿病(DM)是一种代谢疾病,其特征为高血糖症。高血糖症在DM导致在造血干细胞(HSC)的造血过程骨髓功能障碍。本研究的目的是分析辣木oliefera白蛋白(MA)组合的优点,以控制SDF-1和TER-119〜+ VLA-4在骨〜+骨髓的发展。菌素被用来诱发糖尿病在BALB / c小鼠。 MA口服剂量在1在14天期间给予(50%M:50%A),2剂量(75%M:25%A)和剂量3(25%M:75%A)。从小鼠骨髓细胞处理后,分离第15天,和SDF-1的轮廓和TER-119〜+ VLA-4 +细胞,通过流式细胞术进行分析。数据进行统计学分析使用SPSS版本16用于Windows单向ANOVA(P <0.05)和Tukey检验。表明,所有的剂量MA的组合可以降低显著SDF-1的发展,而只有剂量2中的结果(75%M:25%A)有效增加TER-119〜+ VLA-4〜+的发展。在结论,MA组合在控制SDF-1的开发和TER-119〜+ VLA-4〜+在一定剂量的作用。根据研究结果,我们认为MA可能是一个很好的候选人作为糖尿病治疗药物之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号